Skip to main content
Clinical Trials/NCT03937011
NCT03937011
Completed
Not Applicable

A Prospective, Multicenter, Multispecialty Evaluation of STRATAFIX™ Spiral PDS™ Plus Knotless Tissue Control Devices in Robotic Procedures

Ethicon, Inc.8 sites in 3 countries161 target enrollmentDecember 11, 2019

Overview

Phase
Not Applicable
Intervention
Robotic Suturing of gastric sleeve oversew and vaginal cuff closure
Conditions
Bariatric - Sleeve Gastrectomy Staple Line Reinforcement
Sponsor
Ethicon, Inc.
Enrollment
161
Locations
8
Primary Endpoint
Percentage of subjects with no bleeding or mild bleeding (defined as success) at the completion of the suturing at the organ layer (vaginal cuff closure or gastric staple line reinforcement using STRATAFIX™ Spiral PDS™ Plus).
Status
Completed
Last Updated
2 months ago

Overview

Brief Summary

This single-arm, prospective, observational multicenter study will collect clinical data in a post-market setting across two different specialties in Robotic surgical procedures: Bariatric Sleeve gastrectomy (Staple line reinforcement) and Hysterectomy (Vaginal cuff closure). Investigators will perform the procedure using SFX Spiral PDS Plus in compliance with their standard surgical approach and the IFU.

Registry
clinicaltrials.gov
Start Date
December 11, 2019
End Date
November 13, 2023
Last Updated
2 months ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Elect to have a Robotic Bariatric Sleeve Gastrectomy or Robotic Total Hysterectomy where STRATAFIX™ Spiral PDS™ Plus device is used for staple line re-enforcement or vaginal cuff closure, respectively
  • Are willing and able to give consent and comply with all study-related evaluations and treatment scheduled
  • Subjects are ≥ 18 years of age

Exclusion Criteria

  • Physical or psychological condition which would impair study participation or are unwilling or unable to participate in all required study visits
  • Any pre-operative or intra-operative findings identified by the surgeon that may preclude the use of study product
  • Enrolled in a concurrent clinical study (drug/device) that might affect current study primary or secondary endpoints
  • Allergic to poly (p-dioxanon), IRGACARE®\* MP (triclosan) or D\&C Violet No. 2 colorant
  • Pregnant or lactating female subjects as confirmed prior to the procedure
  • Subjects undergoing radical hysterectomy (Type B, C and D) according to Querleu \& Morrow classification or gastric sleeve revision surgery

Arms & Interventions

Stratafix Arm

The single study arm would comprise of two different specialties in Robotic surgical procedures: Bariatric Sleeve gastrectomy (Staple line reinforcement) and Hysterectomy (Vaginal cuff closure).

Intervention: Robotic Suturing of gastric sleeve oversew and vaginal cuff closure

Outcomes

Primary Outcomes

Percentage of subjects with no bleeding or mild bleeding (defined as success) at the completion of the suturing at the organ layer (vaginal cuff closure or gastric staple line reinforcement using STRATAFIX™ Spiral PDS™ Plus).

Time Frame: Intra-op assessment (During Surgery; after suturing of the target tissue, Day of surgery)

The bleeding grade assessment used for the primary endpoint will be made right after the suturing is completed. Any re-bleeding after the initial assessment (just before the removal of the optics and trocars) from the suture line after this assessment will be considered a failure for the primary performance endpoint.

Secondary Outcomes

  • Qualitative Assessment of Suture Handling(Intra-op (at surgery, after suturing of the target tissue layer, Day of surgery))
  • Time to Closure (in minutes/seconds)(Intra-op (during suturing of the target tissue, Day of surgery))
  • Overall procedure time (first incision to skin closure)(Intra-op (during the surgery, Day of surgery))
  • Estimated intra-operative blood loss per institutional standard of care and incidence of subjects requiring blood transfusion(Intra-Op (during the surgery, Day of surgery))
  • Abnormal vaginal discharge (total hysterectomy subjects)(14 days post-perative 90 days post-operative (+/- 30 days), 180 days post-operative (+/- 30 days))
  • C-SATS GEARS score(Intra-op (during the surgery, Day of surgery))
  • Length of stay in hours(Post-Operative up to 48 hrs)
  • Incisional site physical assessment:is suture palpable, suture line intact, or tender (all rated yes/no)(14 days post-perative 90 days post-operative (+/- 30 days), 180 days post-operative (+/- 30 days))
  • Intra-operative leak test in bariatric procedure as per institutional standard of care, if any(Intra-op (during Surgery; Day of surgery))
  • Post-operative male/female dyspareunia related to sutures (total hysterectomy subjects)(90 days post-operative (+/- 30 days), 180 days post-operative (+/- 30 days))

Study Sites (8)

Loading locations...

Similar Trials